Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MicroPort CardioFlow Medtech Corporation
微创心通医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2160)

COMPLETION OF VERY SUBSTANTIAL ACQUISITION AND CONNECTED TRANSACTION INVOLVING ISSUE OF NEW SHARES UNDER SPECIFIC MANDATE IN RELATION TO THE ACQUISITION OF THE TARGET GROUP

Exclusive Financial Adviser to the Target Group

References are made to the announcements of the MicroPort CardioFlow Medtech Corporation (the "**Company**") dated July 16, 2025, September 29, 2025 and December 15, 2025, and the circular of the Company dated November 24, 2025 (the "**Circular**"). Unless otherwise defined, capitalised terms used herein shall have the same meanings as defined in the Circular.

The Board is pleased to announce that all conditions precedent under the Merger Agreement have been satisfied or waived, and the Transaction was completed on December 19, 2025. The Target Company (MicroPort Cardiac Rhythm Management Limited (微創心律管理有限公司)) and its subsidiaries have become indirect subsidiaries of the Company.

The completion of the Merger marks the expansion of the Group's business scope from the interventional treatment of structural heart diseases to cardiac rhythm management, successfully establishing a diversified product platform in the Total Cardio (大心臟) field. It also signifies that the Group now possesses a broader global market presence, further enhancing its global competitiveness and risk resilience. Moving forward, the Group will continuously strengthen business synergies, pursue quality and efficiency improvements, and fully integrate both parties' core technologies and global resources to provide physicians and patients with innovative comprehensive management solutions for heart failure that

covers "all causes, all stages, and the entire course" of the disease, with the ambition to build a leading enterprise of emerging technologies in cardiac diagnosis and therapy.

EFFECTS OF THE TRANSACTION ON THE SHAREHOLDING STRUCTURE OF THE COMPANY

The shareholding structures of the Company (i) immediately before the Closing; and (ii) immediately after the Closing are set out below:

	Immediately before the Closing		Immediately after the Closing	
	Number of Shares	Approximate %	Number of Shares	Approximate %
MicroPort® *(Note 1)*	1,112,855,680	46.12	2,829,741,451	44.45
Mr. Chen Guoming *(Note 2)*	742,954	0.03	742,954	0.01
Mr. Zhang Ruinian *(Note 2)*	90,000	0.004	90,000	0.001
Mr. Philippe Wanstok *(Note 2)*	—	—	18,523,140	0.29
Public shareholders				
Original shareholders of the Target Company (other than those as mentioned above)	80,000	0.003	2,218,518,496	34.85
Other public shareholders	1,298,938,141	53.84	1,298,938,141	20.40
	2,412,706,775	**100.00**	**6,366,554,182**	**100.00**

Notes:

1. Before completion of the Transaction, Shanghai MicroPort Limited, a wholly owned subsidiary of MicroPort®, held 1,112,855,680 Shares. Upon completion of the Transaction, MicroPort International was allotted and issued 1,716,885,771 Shares.

2. Each of Mr. Zhang Ruinian, Mr. Chen Guoming, and Mr. Philippe Wanstok is a Director of the Company. Mr. Philippe Wanstok is interested in 834,000 vested shares of the Target Company, which have been translated to 18,523,140 New Shares held by the trustee of the Target Group's employee long-term incentive scheme upon the Merger becoming effective.

3. The aggregate of the percentage figures in the table above may not add up to the relevant sub-total or total percentage figures shown due to rounding of the percentage figures.

By Order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Hong Kong, December 19, 2025

As of the date of this announcement, the executive Directors are Mr. Zhang Ruinian and Mr. Philippe Wanstok, the non-executive Directors are Mr. Chen Guoming, Dr. Brian Chang, Mr. Deng Aoyi and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Ms. Sun Zhixiang and Dr. Hu Bingshan.